Search hospitals > Arizona > Phoenix
Phoenix Children's Hospital
Claim this profilePhoenix, Arizona 85016
Global Leader in Cancer
Global Leader in Brain Tumor
Conducts research for Leukemia
Conducts research for Acute Lymphoblastic Leukemia
Conducts research for Neuroblastoma
517 reported clinical trials
46 medical researchers
Summary
Phoenix Children's Hospital is a medical facility located in Phoenix, Arizona. This center is recognized for care of Cancer, Brain Tumor, Leukemia, Acute Lymphoblastic Leukemia, Neuroblastoma and other specialties. Phoenix Children's Hospital is involved with conducting 517 clinical trials across 773 conditions. There are 46 research doctors associated with this hospital, such as Jessica Boklan, Alok K. Kothari, Lindsey Hoffman, and Gerard Vockley, MD, PhD.Area of expertise
1Cancer
Global LeaderStage IV
Stage I
Stage II
2Brain Tumor
Global LeaderStage IV
Stage I
Stage II
Top PIs
Jessica BoklanPhoenix Childrens Hospital8 years of reported clinical research
Studies Neuroblastoma
Studies Cancer
31 reported clinical trials
78 drugs studied
Alok K. KothariPhoenix Childrens Hospital8 years of reported clinical research
Studies Cancer
Studies Rhabdomyosarcoma
17 reported clinical trials
41 drugs studied
Lindsey HoffmanPhoenix Childrens Hospital5 years of reported clinical research
Studies Brain Tumor
Studies Neuroblastoma
13 reported clinical trials
24 drugs studied
Gerard Vockley, MD, PhDUPMC Children's Hospital of Pittsburgh2 years of reported clinical research
Studies Phenylketonuria
Studies Genetic Disorders
14 reported clinical trials
17 drugs studied
Clinical Trials running at Phoenix Children's Hospital
Crohn's Disease
Testicular cancer
Wilms Tumor
Neuroblastoma
Brain Tumor
Ovarian Carcinoma
Ovarian Tumors
Testicular Carcinoma
Ovarian Choriocarcinoma
Eosinophilic Esophagitis
Anti-TNF Therapy
for Crohn's Disease in Children
Crohn's disease (CD) is a condition that causes inflammation (swelling, redness) of the lining and wall of the small intestine, large intestine, or both. CD may be associated with abdominal cramps/pain, diarrhea, blood in the stool, weight loss, or delayed growth in children. While the exact cause of CD is not certain it is thought that the immune system located in the intestine reacts abnormally to the large number of bacteria contained there. The investigators think that diet, exposure to antibiotics early in life, and having a family history of CD puts people at increased risk for developing CD. In order to decrease the inflammation doctors use what is called biologic therapy with anti-TNF molecules that can be given through an intravenous or shots. TNF is a chemical made by white blood cells that is involved in inflammation. When this type of treatment is given early after diagnosis it is more effective than when it is given later. The investigators have learned that it is important to give the optimum (ideal) amount of this medicine guided by certain blood tests. The investigators also know that not everyone responds to this therapy but do not understand the reasons for this variability between people. The CAMEO study has been started to help understand what factors are important in determining whether a child with CD completely heals the inflammation after anti-TNF therapy. The investigators will do that by measuring certain markers of inflammation in the blood and stool and by looking at a person's genes (DNA) and how inflammation is controlled in the intestine. These inflammation tests will be done before, during, and after one year of anti-TNF therapy. The investigators will determine how much healing has taken place by comparing the results of the colonoscopy and a special type of MRI that are both done before anti-TNF and then again one year later. The goal in treating CD is to heal both the lining and the wall of the intestine. Children ages 6-17 years who are thought to have CD and are about to undergo their diagnostic colonoscopy are eligible to be enrolled. If they are found to indeed have CD and start an anti-TNF medicine within 6 months they can continue in the study. There are no increased risks of participating in this study beyond those normally associated with having CD and its treatment. By better understanding why the bowel does or does not heal, doctors will be better able to provide personalized care.
Recruiting3 awards Phase 47 criteria
Risankizumab
for Pediatric Crohn's Disease
Crohn's Disease (CD) is a gastrointestinal disease that can cause chronic diarrhea with or without gross bleeding, abdominal pain, weight loss, and fever. This study will assess the pharmacokinetics, efficacy, and safety of risankizumab in pediatric participants with moderately to severely active CD aged 2 to \< 18 years old who have had intolerance or inadequate response to other therapies. Risankizumab is an approved drug for adults with plaque psoriasis, psoriatic arthritis, and CD and is being developed for the treatment of CD in pediatrics. This study is comprised of 3 cohorts that may participate in 3 substudies (SS). Cohort 1(including Sub-cohort 1A) will enroll participants with ages from 6 to less than 18 years. Cohort 2 will enroll participants with ages from 2 to less than 6 years. Cohort 3 will enroll participants with ages from 2 to less than 18 years. SS1 is an open-label induction period where participants will receive a weight-based induction regimen of risankizumab. SS2 is a double-blind maintenance period where participants will be randomized to receive 1 of 2 doses of weight-based induction regimen of risankizumab. SS3 is an open-label extension period where participants will receive risankizumab based off of their response in SS2. Approximately 118 pediatric participants with CD will be enrolled at around 100 sites worldwide. Participants in SS1 will receive risankizumab intravenously during the 12-week induction period. Participants in SS2 will receive risankizumab subcutaneously during the 52-week randomized maintenance period. Participants in SS3 will receive risankizumab subcutaneously during the 208-week open label period. Participants will be followed-up for approximately 140 days. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Recruiting2 awards Phase 3
Guselkumab
for Pediatric Crohn's Disease
This trial tests guselkumab, an anti-inflammatory medication, on children with Crohn's Disease who initially responded well to it. The goal is to see if the benefits last over several months by reducing immune system activity. Guselkumab has shown effectiveness in treating moderate-to-severe psoriasis and psoriatic arthritis.
Recruiting2 awards Phase 3
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Phoenix Children's Hospital?
Phoenix Children's Hospital is a medical facility located in Phoenix, Arizona. This center is recognized for care of Cancer, Brain Tumor, Leukemia, Acute Lymphoblastic Leukemia, Neuroblastoma and other specialties. Phoenix Children's Hospital is involved with conducting 517 clinical trials across 773 conditions. There are 46 research doctors associated with this hospital, such as Jessica Boklan, Alok K. Kothari, Lindsey Hoffman, and Gerard Vockley, MD, PhD.
Where is Phoenix Children's Hospital located?
Phoenix Children's Hospital is located at 1919 E. Thomas Rd., Phoenix, AZ 85016.
Who should I call to ask about financial aid or insurance network?
For financial assistance and insurance-related inquiries at Phoenix Children's Hospital, contact the following departments:
- **Financial Counseling**: For general financial assistance, call 602-933-2000. Available Monday to Friday, 7 am to 6:30 pm MT, and Saturday to Sunday, 8 am to 4:30 pm MT.
- **Customer Service**: For billing inquiries, contact 602-933-8700. Open Monday to Friday, 8 am to 5 pm MT.
- **Financial Assistance Application**: Apply for financial assistance at the Financial Counselor Offices, the Customer Service Department, or through the Phoenix Children's website.
- **Charity, Low-Income & Uninsured Program**: For information, call 602-933-2000.
These departments help with eligibility for financial assistance, understanding billing, and exploring payment and coverage options.
What insurance does Phoenix Children's Hospital accept?
Phoenix Children's Hospital accepts a wide range of health insurance plans, including but not limited to Aetna Health, Inc., America's Choice Provider Network (ACPN), Arizona Complete Health, and Blue Cross Blue Shield of Arizona (BCBSAZ). For transplant procedures, accepted insurance includes Accarent Health, AHCCCS, BCBSAZ, and Cigna LifeSource among others. It is recommended to check with your insurance provider directly to confirm coverage and network status for specific services or procedures at Phoenix Children's Hospital.
What awards or recognition has Phoenix Children's Hospital received?
Phoenix Children's Hospital is renowned for its focus on pediatric malignancy and hematologic disorder research. It participates in over 70 clinical trials for patients with various types of cancers and blood disorders through its Center for Cancer and Blood Disorders. The hospital has achieved association accreditation for human research protection, underscoring its commitment to ethically sound research.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.